Registered title, quoted from ClinicalTrials.gov
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Xiangya Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06702826, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed non-small cell lung cancer;
Inclusion criterion 3
Prior treatment with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor.
Exclusion criterion 6
ECOG 0-1;
Inclusion criterion 2
Requirements for brain metastases: ① measurable brain metastases without radiotherapy; ②SRS/FSRT: the maximum tumor volume of brain metastases was less than 10cm3, the single diameter was less than 3cm, and the total volume of brain metastases involved was less than 15 cm3.
Inclusion criterion 5
Subjects were evaluated for all extracranial disease sites (e.g., by computed tomography (CT) scan and bone scan or positron emission tomography (PET-CT) within 14 days before the first dose.
Inclusion criterion 9
Subjects had to have a baseline brain MRI scan within 14 days before the first dose of medication.
Inclusion criterion 10
Previous (within 5 years) or concurrent other malignant tumors
Exclusion criterion 7
Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative.
Inclusion criterion 12
Patients who are not lactating.
Inclusion criterion 13
Pregnant or lactating women.
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06702826, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 18 years old ≤ 75 years old; Both male and female;
- ECOG 0-1;
- Histologically or cytologically confirmed non-small cell lung cancer;
- Progression with brain metastasis after previous first-line anti-tumor therapy;
- Requirements for brain metastases: ① measurable brain metastases without radiotherapy; ②SRS/FSRT: the maximum tumor volume of brain metastases was less than 10cm3, the single diameter was less than 3cm, and the total volume of brain metastases involved was less than 15 cm3.
- Response to previous checkpoint inhibitor therapy on the initial response assessment;
- If a metastatic lesion of the head has been irradiated, the cumulative radiation dose does not exceed the tolerated dose to all structures.
- For patients with measurable CNS lesions, the longest diameter on MRI images is ≥10mm, which is suitable for repeated and accurate measurement.
- Subjects were evaluated for all extracranial disease sites (e.g., by computed tomography (CT) scan and bone scan or positron emission tomography (PET-CT) within 14 days before the first dose.
- Subjects had to have a baseline brain MRI scan within 14 days before the first dose of medication.
- Estimated survival time > 12 weeks.
- Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative.
- Patients who are not lactating.
- Have definite and good organ functions:
- Provide informed consent voluntarily, and be willing and able to comply with the follow-up, treatment, laboratory testing, and other study requirements specified in the study schedule.
Exclusion Criteria:
Subjects who meet any of the following criteria are not eligible to participate in the study:
- Experienced grade 3-4 intracranial toxicity (pituitary or central nervous system toxicity);
- No measurable intracranial metastatic lesions without radiotherapy;
- Meningeal metastasis;
- If receiving chemotherapy or targeted therapy, the washout period should not exceed 3 weeks; if receiving brain metastasis resection, the washout period should not exceed 2 weeks;
- Have significant autoimmune diseases
- Prior treatment with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor.
- Previous (within 5 years) or concurrent other malignant tumors
- History of anaphylaxis to any monoclonal antibody and/or study drug component.
- A history of or current noninfectious pneumonia/interstitial lung disease requiring systemic glucocorticoids.
- Serious infection within 4 weeks before the first dose.
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Subjects required systemic treatment with corticosteroids (>10mg prednisone equivalent per day) or other immunosuppressive drugs within 14 days before taking the study drug.
- Patients with clinically significant cardiovascular disease
- Enroll in another clinical study at the same time, unless it is an observational, noninterventional clinical study or a follow-up of an interventional study.
- Received live vaccine within 30 days before the first dose, or planned to receive live vaccine during the study.
- Known history of mental illness, substance abuse, alcohol or drug abuse.
- Pregnant or lactating women.
- The presence of any past or current medical conditions, treatments, or laboratory abnormalities may confound the results of the study, interfere with the full participation of the subject in the study, or may not be in the best interest of the subject to participate in the study.
Quoted from ClinicalTrials.gov, NCT06702826, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06702826, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.